Eisai Limited
Global research-driven pharmaceutical company focused on neurology and oncology. Demonstrated capabilities include discovery and development of small molecules and biologics, computational antibody engineering, biomarker assay development for CSF and blood, integration of imaging and fluid biomarkers into trial endpoints, design and conduct of global and adaptive clinical trials, manufacturing and scale-up for oral and parenteral products, liposomal formulation development, and collaborations with academic, industry, and consortium partners to support multi-site trials and diagnostic development.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
US-10253106-B2
View Details
Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
US-10253106-B2
View DetailsProducts
Monoclonal antibody therapeutics targeting amyloid and tau species
Clinical-stage monoclonal antibodies designed to bind and clear pathological amyloid-beta aggregates or tau species, developed with biomarker-driven strategies and target-engagement monitoring.
Small-molecule oncology therapeutics (multi-kinase inhibitors and immune modulators)
Small-molecule kinase inhibitors and immune-modulating agents developed for oncology indications and evaluated in monotherapy and combination regimens, including trials in rare tumor types.
Liposomal cytotoxic formulation for select solid tumors
Liposomal delivery formulation of a microtubule dynamics inhibitor intended to increase intratumoral drug concentration and evaluated in early clinical cohorts.
Monoclonal antibody therapeutics targeting amyloid and tau species
Clinical-stage monoclonal antibodies designed to bind and clear pathological amyloid-beta aggregates or tau species, developed with biomarker-driven strategies and target-engagement monitoring.
Small-molecule oncology therapeutics (multi-kinase inhibitors and immune modulators)
Small-molecule kinase inhibitors and immune-modulating agents developed for oncology indications and evaluated in monotherapy and combination regimens, including trials in rare tumor types.
Liposomal cytotoxic formulation for select solid tumors
Liposomal delivery formulation of a microtubule dynamics inhibitor intended to increase intratumoral drug concentration and evaluated in early clinical cohorts.
Services
Design and execution of global multicenter studies, adaptive platform trials, biomarker-driven prevention trials, and consortium-participating studies.
In-house development and analytical validation of CSF and plasma biomarker assays to support target engagement, diagnosis, and trial screening.
In silico prediction of antibody–antigen interactions, binding energetics, and rational design of amino-acid substitutions using MD and enhanced sampling methods integrated with experimental workflows.
Formulation of liposome-encapsulated cytotoxics to enhance tumor delivery and retention, with supporting early-phase clinical assessment and combination study design.
Design and execution of global multicenter studies, adaptive platform trials, biomarker-driven prevention trials, and consortium-participating studies.
In-house development and analytical validation of CSF and plasma biomarker assays to support target engagement, diagnosis, and trial screening.
In silico prediction of antibody–antigen interactions, binding energetics, and rational design of amino-acid substitutions using MD and enhanced sampling methods integrated with experimental workflows.
Formulation of liposome-encapsulated cytotoxics to enhance tumor delivery and retention, with supporting early-phase clinical assessment and combination study design.
Expertise Areas
- Clinical trial management (Phase I–III, prevention and adaptive platform trials)
- Biomarker assay development for CSF and blood-based diagnostics
- Antibody discovery and engineering supported by computational simulation
- Neuroscience and dementia research with imaging and fluid biomarkers
Key Technologies
- Molecular dynamics and enhanced sampling simulations
- High-performance computing for molecular modeling
- Structural biology (X-ray crystallography, cryo-EM)
- Fully automated immunoassay platforms for plasma biomarkers
News & Updates
Launch of a Phase III prevention study in preclinical Alzheimer’s disease using an anti-amyloid protofibril monoclonal antibody; trial enrolls cognitively unimpaired participants stratified by brain amyloid and uses imaging and fluid biomarkers as endpoints.
Submission of a regulatory application in Japan seeking an additional indication for a multi-kinase inhibitor in unresectable thymic carcinoma based on an open-label multicenter Phase II study.
Presentation of phase I clinical trial results for a liposomal formulation of a microtubule inhibitor in HER2-negative breast cancer cohorts, including response rates, progression-free survival and safety profile.
Oral and poster presentations covering study designs, screening results, safety analyses (ARIA-E), brain amyloid changes, and baseline characteristics across prevention and early-stage Alzheimer’s clinical programs; included presentations on antibody candidates and tau-targeting antibodies.
Academic poster reporting that plasma Aβ1-42/Aβ1-40 ratio measured on a fully automated immunoassay predicted amyloid PET positivity with improved performance when PET centiloid quantification was used.
Publication/presentation describing methods to quantify MTBR-containing tau species in CSF and demonstration of target engagement by an anti-tau antibody candidate in preclinical and clinical contexts.
Launch of a Phase III prevention study in preclinical Alzheimer’s disease using an anti-amyloid protofibril monoclonal antibody; trial enrolls cognitively unimpaired participants stratified by brain amyloid and uses imaging and fluid biomarkers as endpoints.
Submission of a regulatory application in Japan seeking an additional indication for a multi-kinase inhibitor in unresectable thymic carcinoma based on an open-label multicenter Phase II study.
Presentation of phase I clinical trial results for a liposomal formulation of a microtubule inhibitor in HER2-negative breast cancer cohorts, including response rates, progression-free survival and safety profile.
Oral and poster presentations covering study designs, screening results, safety analyses (ARIA-E), brain amyloid changes, and baseline characteristics across prevention and early-stage Alzheimer’s clinical programs; included presentations on antibody candidates and tau-targeting antibodies.
Academic poster reporting that plasma Aβ1-42/Aβ1-40 ratio measured on a fully automated immunoassay predicted amyloid PET positivity with improved performance when PET centiloid quantification was used.
Publication/presentation describing methods to quantify MTBR-containing tau species in CSF and demonstration of target engagement by an anti-tau antibody candidate in preclinical and clinical contexts.